Contamac announced US Food and Drug Administration (FDA) Premarket approval for the Optimum Infinite (tisilfocon A) Orthokeratology Lenses II. The lenses are indicated for use in the reduction of refractive error in nondiseased eyes. They also are indicated for overnight wear for the temporary reduction of myopia up to 6.00 D with eyes having astigmatism up to 1.75 D. Optimum Infinite lenses have an oxygen permeability of 180 Dk.